**Author's response to reviews**

**Title:** Clinico-pathogenetic findings and management of chondrodystrophic myotonia (Schwartz-Jampel syndrome)

**Authors:**
- Dr Nicola C. Ho (honi@grc.nia.nih.gov)
- Stacey S. Sandusky (sanduskyst@grc.nia.nih.gov)
- Victor Madike (madikevi@grc.nia.nih.gov)
- Dr Clair A. Francomano (francomanoccl@grc.nia.nih.gov)
- Marinos M Dalakas (dalakasm@ninds.nih.gov)

**Version:** 3  **Date:** 17 Jun 2003

PDF covering letter

Dear Editor:

We have taken note of the reviewers’ advice and have revised accordingly.

(1) We have replaced myotonica with myotonia in both title and text
(2) We have used carbamazapine in the text instead of tegretol and also stated the dosage
(3) The issue of consanguinity has already been addressed in the original manuscript "He was born to healthy, non-consanguineous parents." This is retained in the revised manuscript.
(4) We have described the clinical examination of the patient in the original manuscript. "Physical examination revealed ..."and the salient clinical features were described.
(5) We have detailed more of the clinical aspects of SJS and address the issue of clinical variability and subtyping of SJS into type 1A and type 1B and type 2 in the discussion section.
(6) We have enlarged the clinical revision to discuss clinical heterogeneity, and the risk of recurrence
(7) As this is a case report and we are already covering clinical and molecular aspects as well as management of SJS, we decide to omit too many details about the molecular findings to make the case report short but succinct.

Many thanks

GB

Nicola Ho et al.